LA JOLLA, Calif., Feb. 10 /PRNewswire/ -- Agouron Pharmaceuticals, Inc.
today announced a change and reorganization of its senior management.
Dr. Barry D. Quart, formerly Senior Vice President, Head of Drug
Development, has been appointed President, Research and Development, and
R. Kent Snyder, formerly Senior Vice President, Head of Commercial Affairs,
has been appointed President, Global Commercial Operations.
Martin Mattingly, formerly Senior Director of Global Marketing Planning,
has been promoted to the position of Vice President, Global Marketing
Planning. Dr. Patrick O'Connor, formerly Senior Director of Oncology
Research, has been promoted to the position of Vice President, Head of
Oncology Research. Dr. Alex Polinsky, formerly chief scientific officer of
the Alanex Research Division, has been promoted to the position of Vice
President, Head of the Alanex Research Division. Dr. Steve Worland, formerly
Senior Director of Antiviral Research, has been promoted to the position of
Vice President, Head of Antiviral Research.
The other members of Agouron's senior management team are: Michael Adam,
Vice President, Head of Worldwide Regulatory Affairs; Neil J. Clendeninn,
M.D., Ph.D., Corporate Vice President, Head of Clinical Affairs; Steven S.
Cowell, Corporate Vice President, Head of Finance and CFO; William C. Denby,
Vice President, Head of Marketing and Sales; Gary E. Friedman, Corporate Vice
President, General Counsel and Secretary; Robert O. Gaskin, Vice President,
Head of Human Resources; Donna C. Nichols, Vice President, Head of Corporate
Communications; Michael D. Varney, Ph.D., Corporate Vice President, Head of
Research; Stephanie Webber, Ph.D., Vice President, Head of Development
Pharmacology; and Glenn R. Zinser, Corporate Vice President, Head of
Operations.
Agouron Pharmaceuticals, Inc., a wholly owned subsidiary of the
Warner-Lambert Company (NYSE: WLA), is an integrated pharmaceutical company
committed to the discovery, development, manufacturing, and marketing of
innovative therapeutic products engineered to inactivate proteins that play
key roles in cancer, AIDS, and other serious diseases. Agouron employs more
than 1200 people of whom approximately 800 are engaged in research and
development. For more information about Agouron, please visit
http://www.agouron.com.
SOURCE Agouron Pharmaceuticals, Inc.
 back to top
Related links:
http://www.agouron.com
Company News On-Call:
http://www.prnewswire.com/comp/019650.html or fax,
800-758-5804, ext. 019650
CONTACT:
Donna Nichols, Vice President, Head of
Corporate Communications of Agouron Pharmaceuticals, Inc.,
858-622-3009
|
